For cardiologists managing heart failure (HF) and chronic kidney disease (CKD), the familiar cycle of “weight up, legs swollen, send to the ED for intravenous [IV] furosemide” may soon give way to a new option.

The FDA’s recent approval of a furosemide autoinjector (Furoscix ReadyFlow, MannKind Corp) to treat edema in adults with HF or CKD offers an at-home treatment that delivers IV-equivalent diuresis in seconds rather than hours.

Furoscix ReadyFlow is the first autoinjector delivering subcutaneous furosemide with systemic exposure comparable to IV dosing, designed specifically to support earlier management of fluid overload outside the hospital.

Fluid overload remains a dominant driver of ED visits, hospitalizations, and readmissions in HF, and it is closely linked to impaired quality of life and higher mortality. HF affects roughly 6.7 million adults in the US, a number projected to exceed 8 million by 2030.

Study Results

FDA approval was based on primary pharmacokinetic endpoints from a crossover study of healthy volunteers aged 45-80 years who received both IV furosemide and the Furoscix ReadyFlow autoinjector in randomized sequence.

The subcutaneous injection achieved ~107% bioavailability relative to IV — meeting bioequivalence criteria — and produced comparable urine volume, sodium excretion, and potassium excretion at 6, 8, and 12 hours.

From Hours to Seconds

Furoscix is already familiar to some cardiologists as an on-body infuser delivering subcutaneous furosemide over about 5 hours. It was approved in 2022 for adults with edema in HF.

Furoscix ReadyFlow uses the same drug but delivers an 80-mg/mL dose via a prefilled autoinjector in under 10 seconds, with symptom relief expected within about an hour.

“This is a game-changer: A delivery system that can be used at home, that is so much more streamlined,” said Marvin Konstam, MD, a professor at Tufts University School of Medicine in Boston and author of an earlier study on at-home treatment of furosemide. “The effort to decongest and keep the patient decongested must go on after discharge: Otherwise, you’re really prone to readmission.”

A New Tool for Early Intervention

As self-administered injectables become standard across other chronic conditions, cardiologists are eyeing a similar shift for fluid management. They are looking to intervene earlier without immediately committing a patient to the ED or an observation hospital stay.

By extending IV-equivalent diuretic exposure beyond the hospital, this treatment offers clinicians a way to treat moderate worsening congestion at home, in HF clinics, or during the post-discharge transition, provided patients are carefully selected and monitored.

In practice, that could mean using Furoscix ReadyFlow for patients who present with early weight gain, ankle edema, or rising jugular venous pressure despite maximized oral diuretics, as an alternative to immediate ED referral.

Patient Autonomy, Clinician Control

Although Furoscix ReadyFlow is presented as a self-administered option, cardiologists will still need to decide who is best suited to use at-home injections and under what guardrails.

Furoscix carries the same class risks as other loop diuretics: dehydration, electrolyte disturbances, hypotension, hyperglycemia in patients with diabetes, and rare ototoxicity, as well as local injection-site effects and photosensitivity.

The autoinjector introduces device-specific issues; if the viewing window does not fully turn yellow or the device is lifted too early, dosing may be incomplete, and a second injection is not recommended without clinician guidance.

That reality may push cardiologists to reserve Furoscix ReadyFlow for cognitively intact patients with reliable support at home and good access to follow-up. Additionally, they may choose to embed Furoscix ReadyFlow into structured HF programs that include remote weight monitoring, symptom checklists, and standing lab orders to monitor kidney function and electrolytes after injections.

In other words, Furoscix ReadyFlow can increase patient autonomy over fluid management but will still require clinician-driven protocols to keep it safe.

Where Does At-Home Use Fit?

Furosemide injections at home are unlikely to replace hospital-based IV diuresis for severe decompensation or pulmonary edema. Instead, its early role may be as a bridge option — a way to treat patients who are slipping into congestion but are still stable enough to remain at home but able to get to hospital care when needed.

Whether this new injection protocol proves to be a niche tool or a broader shift in HF fluid-management strategy will depend on how quickly cardiology practices integrate it into structured pathways and how patients handle self-administration.

Robert J. Mentz, MD, chief of the Heart Failure Section at Duke University School of Medicine in Durham, North Carolina, believes this is a wait-and-see treatment:

“While the new furosemide autoinjector may offer a novel, patient-friendly approach to outpatient decongestion, ultimately, the implementation of this therapy into routine clinical practice will depend on both the ease of the process for insurance approval and additional data from further real-world studies supporting best practices,” he said.

For now, the key message for clinicians is that IV-equivalent diuresis no longer must be tethered to an IV line or a hospital bed — and that opens both opportunities and new responsibilities in managing edema in HF and CKD.

Konstam reported receiving consultant and research funding from SC pharmaceuticals.

Mentz received research support and/or honoraria from Abbott, Abiomed, Alleviant Medical, American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, CVRx, Cytokinetics, Daiichi Sankyo, Edwards, Eli Lilly, Endotronix, Lexicon, Medtronic, Merck, Novartis, Novo Nordisk, Otsuka, Pfizer, Pharmacosmos, Reprieve Cardiovascular, Respicardia, Roche, Rocket Pharmaceuticals, SQ Innovation, Vifor, Windtree Therapeutics, and Zoll.

Lois Anzelowitz Levine is a lifestyle and medical writer who lives in Dallas.